Longitudinal ctDNA Monitoring for Postsurgical Disease Surveillance in Patients with Stage I to IIIB Melanoma
Our findings highlight the prognostic value of post-surgical, personalized ctDNA detection of recurrence and longitudinal disease surveillance in stage I-IIIB melanoma. The impact of ctDNA on real-world clinical decision-making highlights the need to assess outcomes when cancer management is influenced by ctDNA dynamics.
Authors
- Ronald Drengler
- John Hyngstrom (ORCID: https://orcid.org/0000-0002-4833-3838)
- Andrew Poklepovic (ORCID: https://orcid.org/0000-0002-4015-5037)
- T. Vincent
- Bently P. Doonan (ORCID: https://orcid.org/0000-0001-5401-2910)
- Sumedha Sudhaman (ORCID: https://orcid.org/0000-0001-9266-7096)
- Giby V. George (ORCID: https://orcid.org/0009-0007-9529-4564)
- Kristen Elizabeth Rhodin (ORCID: https://orcid.org/0000-0002-3249-5330)
- Michael Krainock (ORCID: https://orcid.org/0000-0003-0081-4584)
- G. Ansstas
- Griffin Budde (ORCID: https://orcid.org/0000-0001-6237-0056)
- Steven Y. Liu
- Meghan J. Mooradian (ORCID: https://orcid.org/0000-0002-8289-8015)
- Karam Khaddour (ORCID: https://orcid.org/0000-0001-6697-3516)
- Jeremy Rosiecki
- Daniel Blake Flora
- Karen Lin
- Elise K. Brunsgaard
- Alan Tan
- Minetta C. Liu
- Ryan J. Sullivan
Institutions
- Rush University Medical Center (US)
- University of Wisconsin–Madison (US)
- Duke University (US)
- Saint Louis University (ES)
- St. Elizabeth Healthcare (US)
- University of Florida (US)
- Massachusetts General Hospital (US)
- Alaska Oncology & Hematology (US)
- Virginia Cancer Institute (US)
- Dana-Farber Cancer Institute (US)
- South Texas Accelerated Research Therapeutics (US)
- Duke Medical Center (US)
- Saint Louis University (US)
- University of the Incarnate Word (US)
Publication Details
- Journal
- Clinical Cancer Research
- Published
- 2026-02-03
- DOI
- https://doi.org/10.1158/1078-0432.ccr-25-3643
- Primary Topic
- Cancer Genomics and Diagnostics
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- U.S. Department of Defense
- Amgen
- Regeneron Pharmaceuticals
- Natera